Sinopharm BIBP COVID-19 vaccine

URI: https://gptkb.org/entity/Sinopharm_BIBP_COVID-19_vaccine

GPTKB entity

Statements (70)

Predicate	Object
gptkbp:instanceOf	vaccine
gptkbp:activeIngredient	inactivated SARS-CoV-2 virus
gptkbp:administeredBy	gptkb:Argentina gptkb:Bahrain gptkb:Bolivia gptkb:Cambodia gptkb:Chile gptkb:China gptkb:Egypt gptkb:Hungary gptkb:Indonesia gptkb:Iran gptkb:Iraq gptkb:Jordan gptkb:Laos gptkb:Mongolia gptkb:Morocco gptkb:Nepal gptkb:Pakistan gptkb:Peru gptkb:Philippines gptkb:Serbia gptkb:Seychelles gptkb:Sri_Lanka gptkb:United_Arab_Emirates gptkb:Zimbabwe
gptkbp:age	18 years and older
gptkbp:approvedBy	gptkb:United_Arab_Emirates 2020-12-09
gptkbp:boosterInterval	6 months after second dose
gptkbp:boosterRecommended	yes
gptkbp:brand	gptkb:BBIBP-CorV gptkb:Sinopharm_COVID-19_vaccine
gptkbp:countryOfOrigin	gptkb:China
gptkbp:developedBy	gptkb:Sinopharm gptkb:Beijing_Institute_of_Biological_Products
gptkbp:dosingSchedule	two doses
gptkbp:effect	~79% (clinical trials)
gptkbp:emergencyServices	gptkb:World_Health_Organization
gptkbp:emergencyUseAuthorizationDate	2021-05-07
https://www.w3.org/2000/01/rdf-schema#label	Sinopharm BIBP COVID-19 vaccine
gptkbp:includedInCOVAX	yes
gptkbp:intervalBetweenDoses	3–4 weeks
gptkbp:phase3TrialLocation	gptkb:Argentina gptkb:Bahrain gptkb:China gptkb:Egypt gptkb:Jordan gptkb:Morocco gptkb:Peru gptkb:United_Arab_Emirates
gptkbp:regulates	over 90 countries
gptkbp:routeOfAdministration	intramuscular injection
gptkbp:sideEffect	fever nausea diarrhea fatigue headache muscle pain chills rash pain at injection site allergic reaction (rare)
gptkbp:storage	2–8°C
gptkbp:target	gptkb:COVID-19
gptkbp:technology	gptkb:virus
gptkbp:WHOEmergencyUseListing	yes
gptkbp:bfsParent	gptkb:COVID-19 gptkb:COVID-19_pandemic
gptkbp:bfsLayer	4